RESEARCH · GLOBAL
AI drug-discovery benchmarks fail on respiratory virus targets; gaps exposed
Standard AI drug-discovery models underperform on polymerase targets for respiratory viruses, revealing benchmark limitations. Signals narrow AI benchmarks can mask real-world capability gaps, a risk for BFSI funding biotech or healthcare AI vendors.
WHY IT MATTERS
Investment and credit committees rely on vendor performance claims tied to published benchmarks; audit teams need to stress-test AI vendor claims against domain-specific failure modes and demand out-of-distribution testing.
Source: Bioengineer.org · 2026-10-16